Key Points
- Amir Heshmatpour acquired 10,000 shares of Neonc Technologies (NASDAQ:NTHI) on April 10 at an average price of $4.89 for $48,900, bringing his direct ownership to 3,042,000 shares (a 0.33% increase) valued at about $14.88 million.
- NTHI opened at $5.44 and is trading well below its 50‑day ($8.56) and 200‑day ($9.07) moving averages with a 52‑week range of $3.20–$12.99, and analysts have a consensus rating of "Reduce" (one Hold, one Sell).
- Neonc focuses on CNS-targeted molecular therapies, with NEO100 in Phase 2a for glioblastoma and preclinical candidate NEO212.
Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) President Amir Heshmatpour acquired 10,000 shares of Neonc Technologies stock in a transaction dated Friday, April 10th. The stock was acquired at an average cost of $4.89 per share, with a total value of $48,900.00. Following the completion of the transaction, the president directly owned 3,042,000 shares of the company's stock, valued at $14,875,380. This trade represents a 0.33% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Neonc Technologies Stock Performance
NASDAQ:NTHI opened at $5.44 on Friday. The firm's 50-day moving average is $8.56 and its 200-day moving average is $9.07. Neonc Technologies Holdings, Inc. has a 52-week low of $3.20 and a 52-week high of $12.99.
Institutional Trading of Neonc Technologies
Institutional investors have recently modified their holdings of the company. Barclays PLC grew its holdings in shares of Neonc Technologies by 5,314.8% during the 4th quarter. Barclays PLC now owns 9,151 shares of the company's stock worth $76,000 after purchasing an additional 8,982 shares in the last quarter. Foundations Investment Advisors LLC acquired a new stake in shares of Neonc Technologies during the 3rd quarter worth approximately $100,000. SLT Holdings LLC acquired a new stake in shares of Neonc Technologies during the 3rd quarter worth approximately $100,000. Goldman Sachs Group Inc. acquired a new stake in shares of Neonc Technologies during the 4th quarter worth approximately $124,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Neonc Technologies during the 4th quarter worth approximately $126,000.
Analyst Ratings Changes
Several brokerages recently issued reports on NTHI. Zacks Research upgraded Neonc Technologies to a "hold" rating in a research note on Wednesday, January 14th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Neonc Technologies in a report on Friday, March 27th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Reduce".
Read Our Latest Stock Report on NTHI
Neonc Technologies Company Profile
(
Get Free Report)
Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
